Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chMIL-38-DOTA
- Development stage
- Phase 1
- Lead developer
- Minomic International
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
chMIL-38-DOTA is an unlabelled chimeric monoclonal antibody conjugate consisting of the anti-Glypican-1 (GPC-1) chimeric antibody chMIL-38 (miltuximab) conjugated to the macrocyclic chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). Developed by Minomic International and its spinout GlyTherix, chMIL-38-DOTA targets GPC-1, a cell surface proteoglycan overexpressed in various solid tumors, including prostate, pancreatic, and bladder (urothelial) cancers, while showing minimal expression in normal tissues. In clinical trials, unlabelled chMIL-38-DOTA has been administered as a pre-dose to block non-tumor binding sites and optimize tumor targeting prior to the infusion of the radiolabeled imaging agent MILGa (67Ga-DOTA-miltuximab). The conjugate is also being investigated for therapeutic applications when radiolabeled with beta-emitting isotopes such as Lutetium-177 (177Lu-DOTA-miltuximab) or alpha-emitting isotopes like Actinium-225.
- Brand names
- MILGaMiltuximab
- Other names
- DOTA-MiltuximabMiltuximab-DOTAmiltuximab tetraxetan
02
Targets
GPC1 (Glypican-1)
Beyond the preview
Go deeper on chMIL-38-DOTA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chMIL-38-DOTA.